ClinicalTrials.gg
CompletedNCT05800093PREDICT-CVDUpdated Oct 29, 2026

Proteomics and Genomics Combined With CT to Predict CVD

An observational study in Coronary Artery Disease Progression, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Completed at 1 site in Netherlands. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Observational

How we know

Updated Oct 29, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
312
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Coronary Artery Disease by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) — 5 open to participants now, 5 under way, none of them phase 3. Coronary Artery Disease · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).

Started
2023
the only one that year
Observational
7 of 11
4 open now
Registered
7th of 11
by date

Among the 11 studies in Coronary Artery Disease by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), this one is the only one that started in 2023, is one of 7 observational ones, and was the 7th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

5 of the 11 studies in Coronary Artery Disease by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Coronary Artery Disease by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), or all of them as a file.
02

Study summary

This study evaluates plaque progression and characteristics in patients with coronary atherosclerosis.

03

Conditions studied

  • Coronary Artery Disease Progression
04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

Adult patients between 50 and 75 years old with nonobstructive coronary artery disease

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients between 50 and 75 years old
  • Subjects at intermediate to high risk for ASCVD
  • Asymptomatic patients without cardiac chest pain
  • Evidence of atherosclerosis on baseline CCTA

Exclusion criteria

Exclusion Criteria:

  • Renal insufficiency, defined as \< 30 ml/min
  • History of cardiovascular events (myocardial infarction, peripheral artery disease and ischemic stroke)
  • Use of lipid lowering therapy other than statin, ezetimibe or bempedoic acid monotherapy
  • Change in lipid lowering therapy in the last 6 months
  • Use of more than two antihypertensive agents
  • No coronary atherosclerosis at baseline imaging
  • Active requiring treatment
  • Atrial fibrillation
  • Any other treatment or condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator
  • Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
312 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Coronary Artery Disease Progression

    Time frame: Through study completion, between 130-156 weeks

Secondary outcomes

  1. Presence of obstructive stenosis

    Time frame: Through study completion, between 130-156 weeks

  2. Progression in number of significant (>50%) and severe (>70%) stenoses

    Time frame: Through study completion, between 130-156 weeks

  3. Total plaque volume progression

    Time frame: Through study completion, between 130-156 weeks

  4. Calcified plaque volume progression

    Time frame: Through study completion, between 130-156 weeks

  5. Non-calcified plaque volume progression

    Time frame: Through study completion, between 130-156 weeks

  6. Low-attenuation plaque volume progression

    Time frame: Through study completion, between 130-156 weeks

  7. Change in Pericoronary Adipose Tissue CT-Attenuation

    Time frame: Through study completion, between 130-156 weeks

  8. CAD-RADS progression (yes/no)

    Time frame: Through study completion, between 130-156 weeks

  9. Progression in number of high-risk plaque characteristics (yes/no)

    Time frame: Through study completion, between 130-156 weeks

07

Study locations

1 site
  • Amsterdam UMC, location AMC
    Amsterdam, Netherlands
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Apr 2026, 38 months.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's 38 months is below that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Jan 2026 → Apr 2026 and completion Jun 2026 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2023
First posted
Apr 5, 2023
StartActual
Jan 12, 2023
Primary completionActual
Apr 8, 2026was Jan 2026
CompletionActual
Apr 8, 2026was Jun 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 29, 2026
Primary completion
Jan 30, 2026→Apr 8, 2026 (actual)
Oct 29, 2026
Study completion
Jun 1, 2026→Apr 8, 2026 (actual)
Oct 29, 2026
Enrollment
310→312
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Active, not recruiting→Completed
    Primary completion Jan 30, 2026→Apr 8, 2026 (now actual)
    Study completion Jun 1, 2026→Apr 8, 2026 (now actual)
    Enrollment 310→312
    + 3 other changes: verification date, oversight details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05800093
Responsible party
E.S.stroes (Principal Investigator, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Apr 5, 2023
Start date
Jan 12, 2023
Primary completion
Apr 8, 2026
Completion
Apr 8, 2026
Last update
Oct 29, 2026

Study contacts

Erik SG Stroes, MD PhD
principal investigator · Amsterdam UMC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion